These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36254892)

  • 21. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
    Cerqueira-Silva T; Shah SA; Robertson C; Sanchez M; Katikireddi SV; de Araujo Oliveira V; Paixão ES; Rudan I; Junior JB; Penna GO; Pearce N; Werneck GL; Barreto ML; Boaventura VS; Sheikh A; Barral-Netto M
    PLoS Med; 2023 Jan; 20(1):e1004156. PubMed ID: 36630477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
    Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
    BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Jiménez-Sepúlveda N; Gras-Valentí P; Chico-Sánchez P; Castro-García JM; Ronda-Pérez E; Vanaclocha H; Peiró S; Burgos JS; Ana Berenguer ; Navarro D; Sánchez-Payá J;
    Vaccine; 2024 Jul; 42(19):4011-4021. PubMed ID: 38760269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
    Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
    Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 vaccine effectiveness by HIV status and history of injection drug use: a test-negative analysis.
    Puyat JH; Wilton J; Fowokan A; Janjua NZ; Wong J; Grennan T; Chambers C; Kroch A; Costiniuk CT; Cooper CL; Lauscher D; Strong M; Burchell AN; Anis A; Samji H;
    J Int AIDS Soc; 2023 Oct; 26(10):e26178. PubMed ID: 37885156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias.
    Andrejko KL; Pry JM; Myers JF; Mehrotra M; Lamba K; Lim E; Fukui N; DeGuzman JL; Openshaw J; Watt J; Jain S; Lewnard JA; Covid-Case-Control Study Team OBOTC
    Am J Epidemiol; 2023 Jun; 192(6):895-907. PubMed ID: 36702469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.
    Skowronski DM; Febriani Y; Ouakki M; Setayeshgar S; El Adam S; Zou M; Talbot D; Prystajecky N; Tyson JR; Gilca R; Brousseau N; Deceuninck G; Galanis E; Fjell CD; Sbihi H; Fortin E; Barkati S; Sauvageau C; Naus M; Patrick DM; Henry B; Hoang LMN; De Wals P; Garenc C; Carignan A; Drolet M; Jassem AN; Sadarangani M; Brisson M; Krajden M; De Serres G
    Clin Infect Dis; 2022 Nov; 75(11):1980-1992. PubMed ID: 35438175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    Price AM; Olson SM; Newhams MM; Halasa NB; Boom JA; Sahni LC; Pannaraj PS; Irby K; Bline KE; Maddux AB; Nofziger RA; Cameron MA; Walker TC; Schwartz SP; Mack EH; Smallcomb L; Schuster JE; Hobbs CV; Kamidani S; Tarquinio KM; Bradford TT; Levy ER; Chiotos K; Bhumbra SS; Cvijanovich NZ; Heidemann SM; Cullimore ML; Gertz SJ; Coates BM; Staat MA; Zinter MS; Kong M; Chatani BM; Hume JR; Typpo KV; Maamari M; Flori HR; Tenforde MW; Zambrano LD; Campbell AP; Patel MM; Randolph AG;
    N Engl J Med; 2022 May; 386(20):1899-1909. PubMed ID: 35353976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
    Lanièce Delaunay C; Martínez-Baz I; Sève N; Domegan L; Mazagatos C; Buda S; Meijer A; Kislaya I; Pascu C; Carnahan A; Oroszi B; Ilić M; Maurel M; Melo A; Sandonis Martín V; Trobajo-Sanmartín C; Enouf V; McKenna A; Pérez-Gimeno G; Goerlitz L; de Lange M; Rodrigues AP; Lazar M; Latorre-Margalef N; Túri G; Castilla J; Falchi A; Bennett C; Gallardo V; Dürrwald R; Eggink D; Guiomar R; Popescu R; Riess M; Horváth JK; Casado I; García MDC; Hooiveld M; Machado A; Bacci S; Kaczmarek M; Kissling E;
    Euro Surveill; 2024 Mar; 29(13):. PubMed ID: 38551095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
    Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC
    BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    Andrews N; Stowe J; Kirsebom F; Toffa S; Rickeard T; Gallagher E; Gower C; Kall M; Groves N; O'Connell AM; Simons D; Blomquist PB; Zaidi A; Nash S; Iwani Binti Abdul Aziz N; Thelwall S; Dabrera G; Myers R; Amirthalingam G; Gharbia S; Barrett JC; Elson R; Ladhani SN; Ferguson N; Zambon M; Campbell CNJ; Brown K; Hopkins S; Chand M; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Apr; 386(16):1532-1546. PubMed ID: 35249272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network.
    Tartof SY; Xie F; Yadav R; Wernli KJ; Martin ET; Belongia EA; Gaglani M; Zimmerman RK; Talbot HK; Thornburg N; Flannery B;
    Influenza Other Respir Viruses; 2023 May; 17(5):e13143. PubMed ID: 37246146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Cerqueira-Silva T; Katikireddi SV; de Araujo Oliveira V; Flores-Ortiz R; Júnior JB; Paixão ES; Robertson C; Penna GO; Werneck GL; Barreto ML; Pearce N; Sheikh A; Barral-Netto M; Boaventura VS
    Nat Med; 2022 Apr; 28(4):838-843. PubMed ID: 35140406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.